New drug combo for relapsed or refractory multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new drug, purinostat mesylate, combined with pomalidomide (a chemotherapy pill) and a low-dose steroid (dexamethasone) for people with multiple myeloma that has returned or stopped responding to prior treatments. The goal is to see if this combination can help control the cancer with manageable side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have multiple myeloma that has come back or stopped responding to at least one prior treatment, including lenalidomide (Revlimid) and a proteasome inhibitor (like Velcade).
- You are between 18 and 75 years old.
- Your myeloma produces a measurable protein (M protein) in your blood or urine, or you have an abnormal free light chain level.
- Your blood counts and organ function (kidney, liver, heart) are within certain limits—your doctor will check these.
- You are not pregnant, breastfeeding, and agree to use effective contraception if you could become pregnant or father a child.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination of drugs for people with multiple myeloma that has come back or stopped responding to previous treatments. The goal is to see if the combination helps control the disease.
This trial tests a new treatment called BMS-986393 (a type of CAR T-cell therapy) compared to standard treatments for adults with multiple myeloma that has come back or is not responding to therapy, and who have already been treated with lenalidomide (Revlimid). The goal is to see if the new treatment works better.
This trial tests a new drug called F182112 against standard treatments for multiple myeloma that has stopped responding to previous therapies. The goal is to see if F182112 works better and is safe for patients whose cancer has become resistant to multiple drug classes.
This trial tests a new combination of three drugs (belantamab mafodotin, cevostamab, and pomalidomide) for patients with multiple myeloma that has returned or stopped responding to previous treatments. The goal is to see if this combination is safe and effective.
This trial tests a new treatment combination for multiple myeloma that has returned or stopped responding to previous therapy and has spread outside the bone marrow. It aims to see if the combination can shrink these tumors and improve outcomes.
This trial tests a new drug called inobrodib combined with two standard treatments (pomalidomide and dexamethasone) for people whose multiple myeloma has come back or did not respond. The goal is to see if this combination can help control the cancer.
Hear when a new Relapsed or Refractory Multiple Myeloma (RRMM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.